Contraindicated (one)bortezomib will improve the degree or influence of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or average CYP2C19 inhibitors may perhaps enhance mavacamten systemic publicity, causing heart failure because of systolic dysfunction. levoketoconazole will increase the degree or influence of bortezomib by influencing hepatic/inte... https://ddd8564689000.blog-mall.com/27290148/lin281632-options